Juvenile myoclonic epilepsy (JME) is a common epileptic syndrome. Before the development of the new antiepileptic drugs (AEDs) after the 1990s, Valproate (VPA) was the first-line treatment in juvenile myoclonic epilepsy. However, the frequent adverse effects and the risk for teratogenicity have resulted in a search for alternative therapies especially in women. Lamotrigine (LTG), topiramate, and levetiracetam, have been used as monotherapy or adjunctive therapy for juvenile myoclonic epilepsy in small patient series. We report a case of a thirty one-years-old female suffered from severe aggravation in myoclonic and generalized tonic-clonic (GTC) seizures after decreasing the lose of VPA and initiating LTG.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Internal Medical Sciences |
Authors | |
Publication Date | July 31, 2013 |
Submission Date | April 15, 2013 |
Published in Issue | Year 2013 Volume: 30 Issue: 2 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.